A new study by researchers Tomljenovic and Shaw question whether the HPV vaccine even prevents cervical cancer.
“On January 12, 2011 the Annals of Medicine published a ground-breaking peer-reviewed paper titled,Human papillomavirus (HPV) vaccine policy and evidence-based medicine: Are they at odds?,1written byrenowned researchers Lucija Tomljenovic, Ph.D.,and Christopher Shaw, Ph.D.”*
“Merck’s clinical trials were flawed because they used an aluminum adjuvant as a ‘placebo’ and only used saline as a comparative for minor, non-serious adverse reactions. With serious adverse reactions, they pooled the results from the saline group and the aluminum ‘placebo’ group. By doing this, they concealed the true rate of serious reactions.”*
Tomljenovic and Shaw cite these key messages:
- To date, the efficacy of HPV vaccines in preventing cervical cancer has not been demonstrated, while vaccine risks remain to be fully evaluated.
- Current worldwide HPV immunization practices with either of the two HPV vaccines appear to be neither justified by long-term health benefits nor economically viable, nor is there any evidence that HPV vaccination (even if proven effective against cervical cancer) would reduce the rate of cervical cancer beyond what Pap screening has already achieved.
- Cumulatively, the list of serious adverse reactions related to HPV vaccination worldwide includes deaths, convulsions, paraesthesia, paralysis, Guillain-Barre Syndrome (GBS), transverse myelitis, facial palsy, chronic fatigue syndrome, anaphylaxis, autoimmune disorders, deep vein thrombosis, pulmonary embolisms, and cervical cancers.
- Because the HPV vaccination programme has global coverage, the long-term health of many women may be at risk against still unknown vaccine benefits.
- Physicians should adopt a more rigorous evidence-based medicine approach, in order to provide a balanced and objective evaluation of vaccine risks and benefits to their patients.
- The almost exclusive reliance on manufacturers’ sponsored studies, often of questionable quality, as a basis for vaccine policy-making should be discontinued.
- Greater efforts should be made to minimize the undue commercial influences on academic institutions and medical research, as this influence may impede unbiased scientific inquiry into important questions about vaccine science and policies.
- Passive adverse event surveillance should be replaced by active surveillance to better understand the true risks associated with vaccines, particularly new vaccines.*
*Learn more: http://www.naturalnews.com/034636_vaccinations_quack_science_medical_journals.html#ixzz1jMeEhOHn